Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ANCHOR CRC
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
- NCT03693170 ↗
- Completed
- Pierre Fabre Medicament
- Standard
We haven't built an HCP commentary report on ANCHOR CRC (encorafenib plus binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ANCHOR CRC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions
- encorafenib; Binimetinib; Cetuximab
- Arms
- 1 Arm · Experimental
- Enrollment
- 95
- Primary outcomes
- Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments
- Sponsor
- Pierre Fabre Medicament with Pfizer, Merck KGaA, Darmstadt, Germany
- Start
- Jan 17, 2019
- Primary completion
- Jun 29, 2020
- Results posted
- Yes
- Registry record
- NCT03693170 · updated Jul 16, 2026
Publications
linked from the registry- Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, Andre T, Carriere Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2023 May 10;41(14):2628-2637. doi: 10.1200/JCO.22.01693. Epub 2023 Feb 10. PubMed 36763936